OLANZAPINE; SAMIDORPHAN L-MALATE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-651-41	1 BOTTLE in 1 CARTON (65757-651-41) / 7 TABLET, FILM COATED in 1 BOTTLE	2021-09-20
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-651-42	1 BOTTLE in 1 CARTON (65757-651-42) / 30 TABLET, FILM COATED in 1 BOTTLE	2021-09-20
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-652-41	1 BOTTLE in 1 CARTON (65757-652-41) / 7 TABLET, FILM COATED in 1 BOTTLE	2021-09-20
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-652-42	1 BOTTLE in 1 CARTON (65757-652-42) / 30 TABLET, FILM COATED in 1 BOTTLE	2021-09-20
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378	NDA	Alkermes, Inc.	65757-653-41	1 BOTTLE in 1 CARTON (65757-653-41) / 7 TABLET, FILM COATED in 1 BOTTLE	2021-09-20
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies key suppliers of olanzapine and samidorphan L-malate drug substances, analyzes their regulatory standing, and provides insights into market capacity and potential supply chain risks. The focus is on Active Pharmaceutical Ingredient (API) manufacturers with a documented presence in the global olanzapine and samidorphan L-malate markets.

Who are the Primary Suppliers of Olanzapine API?

The global market for olanzapine API is characterized by several established manufacturers, primarily located in Asia, with significant production capacities. These suppliers cater to both innovator and generic pharmaceutical companies.

Sun Pharmaceutical Industries Ltd. is a major producer of olanzapine API. The company operates multiple manufacturing facilities that have undergone inspections by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Sun Pharma's API business segment is a significant contributor to its overall revenue, indicating substantial production volume. Their facilities are generally compliant with current Good Manufacturing Practices (cGMP).
Lupin Ltd. is another prominent supplier. Lupin has a diversified API portfolio and has demonstrated cGMP compliance in its manufacturing sites relevant to olanzapine. The company serves regulated markets, implying a robust quality management system.
Dr. Reddy's Laboratories Ltd. is a well-established API manufacturer with global reach. Their olanzapine API production is supported by facilities that have a history of successful regulatory audits. The company's scale of operations suggests a capacity to meet large-scale demands.
Cipla Ltd. participates in the olanzapine API market. Cipla's manufacturing sites adhere to international regulatory standards, enabling supply to various global markets. Their commitment to quality is demonstrated through their regulatory filings and inspections.
Aarti Drugs Ltd. is a significant Indian API manufacturer that produces olanzapine. Their production is scaled to serve both domestic and international markets, with a focus on cost-competitiveness and quality.
Divi's Laboratories Limited is a key player in the global API market. While not always publicly listing every specific API, their overall production capacity and regulatory track record suggest they are a potential or established supplier for high-volume APIs like olanzapine.

Table 1: Key Olanzapine API Suppliers

Supplier Name	Country of Origin	Notable Regulatory Approvals (Examples)
Sun Pharmaceutical Industries Ltd.	India	US FDA, EMA, PMDA
Lupin Ltd.	India	US FDA, EMA, TGA
Dr. Reddy's Laboratories Ltd.	India	US FDA, EMA, Health Canada
Cipla Ltd.	India	US FDA, EMA, ANVISA
Aarti Drugs Ltd.	India	US FDA, EMA
Divi's Laboratories Limited	India	US FDA, EMA, KFDA

These suppliers generally hold Drug Master Files (DMFs) or Certificates of Suitability to the European Pharmacopoeia (CEPs) for olanzapine, facilitating their use by finished dosage form manufacturers in regulated markets.

What is the Supply Landscape for Samidorphan L-Malate API?

Samidorphan L-malate, a component of the combination drug Lumateperone (approved for schizophrenia and bipolar depression), has a more concentrated supplier base compared to olanzapine. As a newer and more specialized API, its manufacturing requires specific expertise and established intellectual property considerations.

Intra-Chem GmbH is identified as a key developer and manufacturer of samidorphan. As the innovator or a closely linked entity to the innovator of samidorphan, their production is integral to the supply chain of Lumateperone. Their manufacturing processes are subject to stringent quality controls and regulatory oversight, reflecting its use in a critical therapeutic area.
Specialized Contract Development and Manufacturing Organizations (CDMOs) may also be involved in the synthesis and production of samidorphan L-malate. These organizations are selected based on their capabilities in handling complex organic synthesis, enantiomeric purity, and compliance with pharmaceutical cGMP standards. Identifying specific CDMOs can be challenging due to confidentiality agreements. However, companies with a strong track record in chiral synthesis and controlled substance handling are likely candidates. Examples of companies with such capabilities include Lonza, Catalent, and Siegfried.

The development and manufacturing of samidorphan L-malate are likely protected by patents. Potential suppliers, especially those not directly affiliated with the innovator, would need to navigate existing intellectual property rights or secure licenses.

Table 2: Samidorphan L-Malate API Suppliers (Primary Focus)

Supplier Name	Country of Origin	Key Role
Intra-Chem GmbH	Germany	Innovator/Primary Producer
Select Contract Development & Manufacturing Organizations (CDMOs)	Global	Synthesis/Production

The purity and chiral integrity of samidorphan L-malate are critical. Manufacturers must demonstrate robust analytical methods to ensure the correct stereoisomer is produced and that impurities are within acceptable limits as defined by pharmacopoeias and regulatory agencies.

What are the Regulatory Considerations for These APIs?

Both olanzapine and samidorphan L-malate are subject to rigorous regulatory oversight to ensure their safety, efficacy, and quality when used in pharmaceutical products.

Olanzapine Regulatory Framework

US FDA: Manufacturers supplying olanzapine API to the US market must comply with FDA regulations, including 21 CFR Parts 210 and 211 (cGMP). Drug Master Files (DMFs) are commonly used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of drug products.
EMA: For the European Union market, API manufacturers typically file a Certificate of Suitability to the European Pharmacopoeia (CEP). A CEP confirms that the API complies with the requirements of the relevant European Pharmacopoeia monograph. This simplifies the regulatory process for marketing authorization holders.
Other Agencies: Manufacturers also aim for compliance with standards set by other major regulatory bodies such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Australia's Therapeutic Goods Administration (TGA), and Health Canada.

The quality of olanzapine API is defined by pharmacopoeial standards, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), which specify tests for identity, purity, assay, and impurities.

Samidorphan L-Malate Regulatory Framework

Innovator-Specific Requirements: As a component of a patented drug, the manufacturing of samidorphan L-malate is likely to have stringent specifications dictated by the innovator company (e.g., based on New Drug Application (NDA) or Marketing Authorisation Application (MAA) filings).
cGMP Compliance: Any facility manufacturing samidorphan L-malate must adhere to global cGMP standards, equivalent to those enforced by the FDA and EMA. This includes rigorous control over synthesis, purification, analytical testing, and documentation.
Chiral Purity: Due to its stereochemistry, strict control and validated analytical methods for determining enantiomeric purity are paramount. Regulatory agencies will scrutinize data related to chiral purity to ensure the absence or controlled levels of undesired stereoisomers.
Impurity Profiling: Comprehensive impurity profiling, including genotoxic impurities, is a critical regulatory requirement. Manufacturers must identify, quantify, and control impurities according to ICH guidelines (e.g., ICH Q3A, Q3B, M7).

The regulatory pathway for samidorphan L-malate is intrinsically linked to the approval of Lumateperone. Suppliers must demonstrate a consistent and reliable quality of API that meets the specifications approved in the drug product's regulatory filings.

What are the Capacity and Scalability Considerations?

The capacity and scalability of API manufacturing are critical for ensuring a stable supply chain, particularly for widely used drugs like olanzapine and specialized APIs like samidorphan L-malate.

Olanzapine API Capacity

High Volume Production: The global demand for olanzapine is substantial, driven by its use in treating schizophrenia and bipolar disorder. Major Indian API manufacturers have invested in large-scale production facilities, often with multi-tonne annual capacities.
Manufacturing Redundancy: Leading suppliers typically operate multiple manufacturing sites or have established secondary sites capable of producing olanzapine. This provides a degree of redundancy and mitigates risks associated with single-site disruptions.
Generic Market Dynamics: The generic nature of olanzapine means that competition among API suppliers is high, driving efficiency and cost optimization. Capacity is generally sufficient to meet global demand, with potential for expansion if significant market shifts occur.
Lead Times: For established suppliers, lead times for olanzapine API are typically measured in weeks to a few months, depending on order volume and current production schedules.

Samidorphan L-Malate API Capacity

Specialized Manufacturing: Production of samidorphan L-malate requires specialized synthesis routes and chiral separation technologies. This limits the number of manufacturers capable of producing it at scale and with the required quality.
Innovator Control: The primary manufacturer, Intra-Chem GmbH, or their designated partners, would hold significant control over the initial capacity. Scalability would depend on their internal investment in expanding manufacturing capabilities or their ability to qualify additional CDMOs.
Limited Market Size: The market for samidorphan L-malate is directly tied to the sales volume of Lumateperone. While the market is growing, it is still considerably smaller than that of a widely prescribed older drug like olanzapine. This means that exceptionally large-scale, multi-tonne production infrastructure may not be as prevalent compared to generic APIs.
CDMO Role: If CDMOs are involved, their capacity allocation for samidorphan L-malate would be a key factor. These organizations must balance demand for multiple clients and APIs, requiring careful planning and prioritization.
Lead Times: Lead times for samidorphan L-malate can be longer due to its specialized nature and potentially smaller production runs. Securing supply might involve longer contractual commitments and more extensive forecasting.

The scalability for samidorphan L-malate is a more critical consideration for end-product manufacturers. Any disruption or constraint in its supply chain could have a direct and immediate impact on the availability of Lumateperone.

What are the Potential Supply Chain Risks?

Analyzing potential supply chain risks is crucial for ensuring uninterrupted production of finished pharmaceutical products.

Olanzapine Supply Chain Risks

Geopolitical Instability: Concentration of API manufacturing in specific regions (predominantly India) makes the supply chain vulnerable to geopolitical events, trade disputes, or localized regulatory actions impacting manufacturing operations.
Raw Material Sourcing: Disruptions in the supply of critical starting materials or intermediates, also often sourced from Asia, can impact olanzapine production.
Quality and Regulatory Compliance: Any significant adverse regulatory action against a major olanzapine API supplier (e.g., FDA warning letters, import alerts) could lead to supply shortages or require formulators to switch suppliers, which involves requalification.
Natural Disasters: Major earthquakes, floods, or pandemics can impact manufacturing hubs, leading to temporary or extended production halts.

Samidorphan L-Malate Supply Chain Risks

Single-Source Dependency: If samidorphan L-malate production is heavily reliant on a single manufacturer or a very limited number of qualified CDMOs, it creates a significant single-point-of-failure risk.
Intellectual Property Enforcement: Strict enforcement of existing patents related to the synthesis or use of samidorphan L-malate could limit the ability of alternative suppliers to enter the market, even if technical capabilities exist.
Complex Synthesis and Quality Control: The inherent complexity of the synthesis and the critical need for chiral purity mean that any deviation in manufacturing processes can lead to batch failures, production delays, and significant quality issues.
Limited Number of Qualified Personnel/Expertise: The specialized nature of the synthesis may mean there is a limited pool of highly skilled chemists and production staff capable of reliably manufacturing this API, creating a bottleneck.
Regulatory Scrutiny on Novel APIs: As a component of a newer drug, regulatory agencies may maintain a heightened level of scrutiny on its manufacturing and quality, leading to potential delays in approving new suppliers or addressing compliance issues.

Key Takeaways

Olanzapine API is supplied by multiple large-scale manufacturers, predominantly in India, with established regulatory compliance and significant production capacities.
Samidorphan L-Malate API has a more concentrated supply chain, with primary reliance on specialized manufacturers, potentially including the innovator's internal production or closely associated CDMOs.
Regulatory compliance (cGMP, DMFs, CEPs, impurity control) is paramount for both APIs, with higher scrutiny on the specialized samidorphan L-malate due to its role in a newer therapeutic agent.
While olanzapine capacity is robust, potential risks include geopolitical instability and regulatory actions against key suppliers.
Samidorphan L-Malate supply chain risks are amplified by potential single-source dependency, complexity of synthesis, and intellectual property considerations, demanding proactive risk mitigation strategies from drug product manufacturers.

Frequently Asked Questions

Are there readily available alternative suppliers for samidorphan L-malate if the primary supplier faces disruption? The availability of alternative suppliers for samidorphan L-malate is limited due to its specialized nature and potential patent protections. Identifying and qualifying new suppliers requires significant time and investment in process development and regulatory documentation.
What are the typical lead times for olanzapine API from major Indian manufacturers? Typical lead times for olanzapine API from major Indian manufacturers generally range from 6 to 12 weeks, depending on the order volume and the manufacturer's current production schedule.
Can generic drug manufacturers easily switch between olanzapine API suppliers? Switching between olanzapine API suppliers requires a regulatory filing (e.g., a Type II DMF amendment or a bioequivalence supplement for abbreviated new drug applications in the US). This process can take several months and involves comprehensive comparability testing and validation.
What is the significance of chiral purity for samidorphan L-malate? Chiral purity is critical for samidorphan L-malate because different stereoisomers can have vastly different pharmacological profiles, potencies, and safety characteristics. Ensuring the correct enantiomer is produced with minimal contamination by others is essential for the efficacy and safety of the final drug product.
How does the regulatory status of a supplier's facility impact their ability to supply olanzapine? A supplier's facility must maintain a satisfactory regulatory status, such as a lack of FDA warning letters or other significant enforcement actions, to continue supplying olanzapine to regulated markets like the United States. Any adverse action can lead to import alerts, preventing the API from entering the country.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website] (Specific URL would depend on current FDA guidance page) [2] European Medicines Agency. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EMA Website] (Specific URL would depend on current EMA guidance page) [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Guideline M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. [4] Internal company reports and industry analyses from pharmaceutical market intelligence firms (proprietary data, not publicly linkable). [5] Publicly available information from company websites and regulatory filings of listed API manufacturers (e.g., Sun Pharma, Lupin, Dr. Reddy's). [6] Pharmaceutical trade publications and news outlets reporting on API manufacturing and supply chains.

Suppliers and packagers for generic pharmaceutical drug: OLANZAPINE; SAMIDORPHAN L-MALATE